Raloxifene glucuronidation in human intestine, kidney, and liver microsomes and in human liver microsomes genotyped for the UGT1A1*28 polymorphism

Drug Metabolism and Disposition

Volumn 39, Issue 12, 2011, Pages 2347-2354

  Lušin, Tina Trdan ^a   Trontelj, Jurij ^a   Mrhar, Aleš ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; GLUCURONOSYLTRANSFERASE 1A1; RALOXIFENE; RALOXIFENE 4' BETA GLUCURONIDE; RALOXIFENE 6 BETA GLUCURONIDE; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG GLUCURONIDATION; ENZYME KINETICS; ENZYME SPECIFICITY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INCUBATION TIME; INHIBITION KINETICS; INTESTINE; INTESTINE MICROSOME; KIDNEY MICROSOME; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; MICROSOME; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TISSUE SPECIFICITY; WILD TYPE;

GENOTYPE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; INTESTINES; KIDNEY; MICROSOMES, LIVER; POLYMORPHISM, GENETIC; RALOXIFENE;

EID: 81855173545     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.041897     Document Type: Article

References (27)

1. Bae JW, Choi CI, Lee JH, Jang CG, Chung MW, and Lee SY (2011) Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects. Eur J Clin Pharmacol 67:39-45.
2. Bock KW and Köhle C (2009) Topological aspects of oligomeric UDP-glucuronosyltransferases in endoplasmic reticulum membranes: advances and open questions. Biochem Pharmacol 77:1458-1465.
3. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, and Oude Elferink RP (1995) The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 333:1171-1175.
4. Briggs B, Baker PJ, Belvo MD, Black TD, Getman BG, Kemp CAJ, Muth WL, Perun TJ, Strobel Jr RJ, Paschal JW, et al. (1999) Microbial process for preparation of glucuronides of raloxifene. J Ind Microbiol Biotechnol 23:194-197.
5. Bryant HU, Glasebrook AL, Yang NN, and Sato M (1999) An estrogen receptor basis for raloxifene action in bone. J Steroid Biochem Mol Biol 69:37-44. (Pubitemid 29305524)
6. Dodge JA, Lugar CW, Cho S, Short LL, Sato M, Yang NN, Spangle LA, Martin MJ, Phillips DL, Glasebrook AL, et al. (1997) Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity. J Steroid Biochem Mol Biol 61:97-106. (Pubitemid 27395747)
7. Gordon ER, Sommerer U, and Goresky CA (1983) The hepatic microsomal formation of bilirubin diglucuronide. J Biol Chem 258:15028-15036. (Pubitemid 14175755)
8. Hochner-Celnikier D (1999) Pharmacokinetics of raloxifene and its clinical application. Eur J Obstet Gynecol Reprod Biol 85:23-29.
9. Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, and Ratain MJ (2002) UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:43-47. (Pubitemid 34982202)
10. Jeong EJ, Liu X, Jia X, Chen J, and Hu M (2005a) Coupling of conjugating enzymes and efflux transporters: impact on bioavailability and drug interactions. Curr Drug Metab 6:455-468. (Pubitemid 41300790)
11. Jeong EJ, Liu Y, Lin H, and Hu M (2005b) Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10. Drug Metab Dispos 33:785-794. (Pubitemid 40686632)
12. Kemp DC, Fan PW, and Stevens JC (2002) Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 30:694-700. (Pubitemid 34579104)
13. Miners JO, Mackenzie PI, and Knights KM (2010) The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev 42:196-208.
14. Ohno S and Nakajin S (2009) Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32-40.
15. Peterkin VC, Bauman JN, Goosen TC, Menning L, Man MZ, Paulauskis JD, Williams JA, and Myrand SP (2007) Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes. Br J Clin Pharmacol 64:458-468. (Pubitemid 47404310)
16. Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM, and Miners JO (2007) Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther 321:137-147. (Pubitemid 46456976)
17. Rowland A, Elliot DJ, Knights KM, Mackenzie PI, and Miners JO (2008a) The "albumin effect"and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9. Drug Metab Dispos 36:870-877. (Pubitemid 351574884)
18. Rowland A, Knights KM, Mackenzie PI, and Miners JO (2008b) The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos 36:1056-1062. (Pubitemid 351717462)
19. Strassburg CP (2008) Pharmacogenetics of Gilbert's syndrome. Pharmacogenomics 9:703-715.
20. Teeter JS and Meyerhoff RD (2002) Environmental fate and chemistry of raloxifene hydrochloride. Environ Toxicol Chem 21:729-736. (Pubitemid 36090379)
21. Trdan T, Roškar R, Trontelj J, Ravnikar M, and Mrhar A (2011) Determination of raloxifene and its glucuronides in human urine by liquid chromatography-tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci 879:2323-2331.
22. Trontelj J, Bogataj M, Marc J, and Mrhar A (2007) Development and validation of a liquid chromatography-tandem mass spectrometry assay for determination of raloxifene and its metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 855:220-227. (Pubitemid 47212014)
23. Trontelj J, Marc J, Zavratnik A, Bogataj M, and Mrhar A (2009) Effects of UGT1A1*28 polymorphism on raloxifene pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 67:437-444.
24. Wu CY and Benet LZ (2005) Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharmacol Res 22:11-23.
25. Yamanaka H, Nakajima M, Katoh M, and Yokoi T (2007) Glucuronidation of thyroxine in human liver, jejunum, and kidney microsomes. Drug Metab Dispos 35:1642-1648. (Pubitemid 47296059)
26. Yoder Graber AL, Ramírez J, Innocenti F, and Ratain MJ (2007) UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers. Pharmacogenet Genomics 17:619-627. (Pubitemid 47057711)
27. Zhang D, Zhang D, Cui D, Gambardella J, Ma L, Barros A, Wang L, Fu Y, Rahematpura S, Nielsen J, et al. (2007) Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism. Drug Metab Dispos 35:2270-2280. (Pubitemid 350146214)